Ureter Cancer - Pipeline Review, H2 2020
- $ 2000
- April 2024
- 363 pages
Pamiparib (BGB-##) is under development f or the treatment of advanced or metastatic adenocarcinoma of the stomach or gastro esophageal junction, relapsed or ref ractory solid tumors including recurrent glioblastoma multif orme (GBM), cervical cancer, bile duct cancer, peripheral nerve sheath cancer, ovarian cancer, endometrial cancer, triple negative breast cancer, non- squamous non-small cell lung cancer, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, leiomyosarcoma, undiff erentiated pleomorphic sarcoma,dediff erentiated liposarcoma, myxof ibrosarcoma,primary peritoneal cancer, f allopian cancer, metastatic castration-resistant prostate cancer (mCRPC), high-grade glioma, low - grade glioma, colorectal cancer, metastatic adenocarcinoma of the pancreas, muscle invasive bladder cancer, transitional cell cancer(urothelial cell cancer), small-cell lung cancer and pancreatic cancer.